StockTipsArenaBeta

BUY Granules India — Vikas Sethi, Sethi Finmart

BUYGranules India
Granules India share price target & all analyst calls

byVikas Sethi, Sethi FinmartHorizon: 1–3 months22 Oct 2026via Zee Business (Live)

Entry₹812Inferred
Target₹845
Total upside +4.06%
Stop loss₹790-2.71% risk
CMP₹8171h ago
Active+0.62%+3.43%upside left 3 mo left
Follow Vikas Sethi for new calls(38% target hit, 131 closed calls)Get alertsWatch GRANULES for new buy/sell callsGet alertsSee 42 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:23 pm IST
5 supporting1 neutral3 opposing
Supports the BUY call (5)

Granules India Eyes 180-Day Exclusivity on Generic Ruxolitinib

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Granules India has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, potentially qualifying for first-to-file status and 180 days of generic exclusivity.

NSE · Press Release·7 Oct · 2w ago

(opens in new tab)

Granules India has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, potentially qualifying for 180 days of generic drug exclusivity in the U.S. market.

BSE · Company Update·7 Oct · 2w ago

(opens in new tab)

Granules India incorporates wholly owned subsidiary in Brazil

NewsCnbc-Tv18·2 Oct · 3w ago

(opens in new tab)

4 advisors have active long-term BUY calls on this stock

Advisor consensus · adjacent horizon·1 Oct · 3w ago

Neutral / worth noting (1)

Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained

NewsGoogle News·19 Oct · 3d ago

(opens in new tab)
Weighs against the BUY call (3)

MACD below its signal line — bearish momentum

Technicals · macd·22 Oct · today

US FDA Starts Inspection at Granules India’s Telangana Plant

NewsGoogle News·19 Oct · 3d ago

(opens in new tab)

Granules India Faces US FDA Inspection At Gagillapur Facility

NewsGoogle News·19 Oct · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Granules India

All analyst calls on Granules India

More from Vikas Sethi, Sethi Finmart

Every call and its outcome